Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
A sharp and unusual divergence has opened up in Accenture's lending market. Short interest has fallen nearly 12% over the past week to 3.5% of the free float. Yet the cost to borrow the stock has surged from 0.60% to 6.78%, a 755% jump in seven days. Those two facts are pulling in opposite directions, and that tension is the story.
Why this matters
When fewer shares are shorted but borrowing them suddenly costs far more, it usually means the remaining shorts are concentrated in a smaller, harder-to-borrow pool. This is not a squeeze in the traditional sense. Availability remains generous at 1,104%, meaning there are more than eleven shares available to borrow for every one currently lent out. The lending pool is not empty. But something changed in its composition on October 13 sharply enough to push the daily cost to borrow to its highest level in over a month.
Short interest stood at roughly 24.5 million shares at the start of October. By October 13 it had fallen to 21.6 million. The earnings print on October 1 delivered an 8.5% single-day gain and a 13.6% five-day move. That outcome forced coverage. The stock has now risen 9.3% over the past week and 16.9% over the past month, closing at $214.96 on October 14. Bears holding pre-earnings positions have had a difficult fortnight.
The ORTEX short score sits at 38, down from 40 a week ago. That directional move confirms that the overall short-side positioning on the name is easing, not intensifying.
Against that backdrop, the options picture stands out. The put/call ratio hit 1.06 on October 14, a 52-week high and 2.16 standard deviations above its 20-day mean of 0.98. That is a notable shift. The previous earnings preview noted a PCR reading below the mean, with the market tilted toward calls. The PCR is now at the opposite extreme. This could reflect fresh hedging after a 17% one-month rally, or positioning around the October 14 earnings call itself. Either way, the options market is no longer as unambiguously bullish as it was a fortnight ago.
BlackRock added 5 million shares in the quarter to September 30, bringing its holding to 62.2 million shares, or 10.4% of the company. State Street and Charles Schwab also added meaningfully. The analyst consensus target stands at $223.78, implying around 4% upside from current levels. That is a more modest cushion than the 14% implied upside noted in last week's articles, reflecting how quickly the stock has closed the gap to Street targets post-earnings.
Retail attention is also elevated. The ORTEX Wikipedia views signal registered a z-score of 2.17 as of October 2, well above the company's own 90-day history.
The divergence between falling short interest and rising borrow costs bears watching. If availability begins to tighten meaningfully alongside the CTB spike, the picture changes.
See the live data behind this article on ORTEX.
Open ACN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
